HealthQuartzabout 4 hours ago
Biogen buys RayThera for up to $1 billion
1 min read
Biogen is acquiring anti-inflammatory drug startup RayThera for up to $1 billion. The deal gives Biogen access to RayThera's pipeline of anti-inflammatory therapies. The acquisition expands Biogen's presence in inflammation and immunology.
Level
Hype check
Tap to vote and see what everyone thinks.
